×

Immunomedics Announces Five Presentations at 2015 ASCO Focusing on Antibody-Drug Conjugate Programs

MORRIS PLAINS, N.J., May 14, 2015 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (Nasdaq:IMMU) today announced that two of its five abstracts submitted to the 2015 Annual Meeting of the American Society of Clinical Oncology (ASCO) have been accepted as oral presentations.

The two oral presentations will be on the Company's second generation antibody-drug conjugate (ADC) programs for solid cancer therapy. Leading that program is sacituzumab govitecan, an anti-TROP-2 antibody conjugated with SN-38, an active drug from irinotecan. Irinotecan is approved for the treatment of patients with colorectal cancer. Results from a Phase 2 study of sacituzumab govitecan in patients with advanced lung cancer will be updated in one of the 2 oral presentations. In addition to this oral presentation, results with sacituzumab govitecan in patients with late-stage triple-negative breast and gastrointestinal cancers will be reported in a Poster Discussion and a Poster Sessions, respectively.

Also presented, in the same Oral Abstract Session as sacituzumab govitecan, will be initial results from a Phase 2 study of labetuzumab govitecan, another SN-38-containing ADC, for patients with metastatic colorectal cancer. The fifth presentation will feature a pilot study on TF2, a bispecific antibody, for pretargeted imaging of breast cancer in a Poster Session.

The ASCO conference will be held at the McCormick Place Convention Center in Chicago, Illinois, from May 29 – June 2, 2015. Details of the five presentations are listed below (all times are in Central Time):

Saturday, May 30, 2015

- Therapy of refractory/relapsed metastatic triple-negative breast cancer (TNBC) with an anti-ΤROP-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): Phase I/II clinical experience (Bardia, et al.)
Poster Discussion Session: Breast Cancer – Triple-negative/Cytotoxics/Local Therapy
Abstract #1016, Poster Board #130
3:00 p.m. - 4:15 p.m.
N Hall B1

Sunday, May 31, 2015

- Improvement in imaging of metastatic breast cancer (BC) with a novel pretargeted immune-PET targeting CEA: First clinical results (Rousseau, et al.)
Poster Session: Tumor Biology
Abstract #11059, Poster Board #272
8:00 a.m. - 11:30 a.m.
S Hall A

Monday, June 1, 2015

- Therapy of gastrointestinal malignancies with an anti-ΤROP-2-SN-38 antibody-drug conjugate (ADC) (sacituzumab govitecan): Phase I/II clinical experience (Starodub, et al.)
Poster Session: Gastrointestinal (Colorectal) Cancer
Abstract #3546, Poster Board #38
8:00 a.m. - 11:30 a.m.
S Hall A

Tuesday, June 2, 2015

- Therapy of advanced metastatic lung cancer with an anti-ΤROP-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): Phase I/II clinical experience (Guarino, et al.)
Oral Abstract Session: Developmental Therapeutics – Clinical Pharmacology and Experimental Therapeutics
Abstract #2504
9:12 a.m. - 9:24 a.m.
S100a
- A new anti-CEA-SN-38 antibody-drug conjugate (ADC), IMMU-130, is active in controlling metastatic colorectal cancer (mCRC) in patients refractory or relapsing after irinotecan-containing chemotherapies: Initial results of a Phase I/II study (Dotan, et al.)
Oral Abstract Session: Developmental Therapeutics – Clinical Pharmacology and Experimental Therapeutics
Abstract #2505
9:24 a.m. - 9:36 a.m.
S100a

About Immunomedics

Immunomedics is a clinical-stage biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Immunomedics' advanced proprietary technologies allow the Company to create humanized antibodies that can be used either alone in unlabeled or "naked" form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins. Using these technologies, Immunomedics has built a pipeline of nine clinical-stage product candidates. Immunomedics has an ongoing collaboration with UCB, S.A. (UCB), to whom the Company licensed epratuzumab for the treatment of all non-cancer indications worldwide. UCB expects Phase 3 data in systemic lupus erythematosus in the first half of 2015. Immunomedics is exploring epratuzumab in oncology in collaboration with independent cancer study groups. Immunomedics' most advanced candidate to which it retains worldwide rights for all indications is 90Y-clivatuzumab tetraxetan. The Company initiated a Phase 3 registration trial in January 2014 in patients with advanced pancreatic cancer and expects patient enrollment to be completed in calendar year 2016. Immunomedics' portfolio of wholly owned product candidates also includes antibody-drug conjugates (ADCs) that are designed to deliver a specific payload of a chemotherapeutic directly to the tumor while reducing overall toxic effects that are usually found with conventional administration of these chemotherapeutic agents. Immunomedics' most advanced ADCs are sacituzumab govitecan (IMMU-132) and labetuzumab govitecan (IMMU-130), which are in Phase 2 trials for a number of solid tumors and metastatic colorectal cancer, respectively. Immunomedics also has a number of other product candidates that target solid tumors and hematologic malignancies, as well as other diseases, in various stages of clinical and pre-clinical development. These include bispecific antibodies targeting cancers and infectious diseases as T-cell redirecting immunotherapies, as well as bispecific antibodies for next-generation cancer and autoimmune disease therapies, created using its patented DOCK-AND-LOCK® protein conjugation technology. The Company believes that its portfolio of intellectual property, which includes approximately 267 active patents in the United States and more than 400 foreign patents, protects its product candidates and technologies. Immunomedics' strength in intellectual property has resulted in a top-8 ranking in the Biotechnology industry by the Patent Board for the 2014 fiscal year. For additional information on the Company, please visit its website at www.immunomedics.com. The information on its website does not, however, form a part of this press release.

This release, in addition to historical information, may contain forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Such statements, including statements regarding clinical trials (including the funding therefor, outcomes, timing or associated costs), out-licensing arrangements (including the timing and amount of contingent payments), forecasts of future operating results, potential collaborations, and capital raising activities, involve significant risks and uncertainties and actual results could differ materially from those expressed or implied herein. Factors that could cause such differences include, but are not limited to, new product development (including clinical trials outcome and regulatory requirements/actions), our dependence on UCB for the further development of epratuzumab for non-cancer indications, risks associated with the outcome of pending litigation and competitive risks to marketed products, and availability of required financing and other sources of funds on acceptable terms, if at all, as well as the risks discussed in the Company's filings with the Securities and Exchange Commission. The Company is not under any obligation, and the Company expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACT: For More Information: Dr. Chau Cheng Senior Director, Investor Relations & Corporate Secretary (973) 605-8200, extension 123 ccheng@immunomedics.comSource:Immunomedics, Inc.